The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.

Creating an accessible office allows those most in need to receive care.

Andrew S. Morgenstern, OD, FAAO, FNAP, joins Dr. Korik to discuss a newly published study on the incidence of keratoconus among pediatric patients in a Chicago-based study. The pair also discuss the International Keratoconus Academy, and Morgenstern's experience working at Walter Reed Medical Center.

The new service, PolicyWatch, allows optometric practices and service providers as well as telemedicine solution companies to access real-time policy changes in their area of practice, spanning all 50 states and the District of Columbia.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies, and much more.

Control measures in China are ahead of US measures.

Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

Trial findings show efficacy of lotilaner for killing mites

Catch up on what happened in optometry during the week of April 8-April 12.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

The optometry school, founded in 1904, was the first of its kind in California.

The company selected LNZ100, designed to treat presbyopia, as its lead candidate and expects to submit an NDA in mid-2024.